Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03529045 · ClinicalTrials.gov registry record
Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.
A clinical trial, sponsored by LivaNova.
- Completed
- Registry status
- 827
- Enrollment target
NCT03529045: Completed study, sponsored by LivaNova.
NCT03529045 is a clinical trial that has completed, run by LivaNova. The registered enrollment target is 827 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03529045 has completed, sponsored by LivaNova.
- COMPLETED
- Registry status
- 827 participants
- Enrollment target
Study Summary
Multicenter global post-market registry of subjects diagnosed with drug resistant epilepsy and treated with the VNS Therapy System.
Primary Outcome
The average seizure frequency per month over the last 3 months (by type) will be collected
Interventions
- DEVICE Vagus Nerve Stimulation (VNS) Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 827 participants |
| Start Date | 2018-02-05 |
| Est. Completion | 2024-09-11 |
What the finished NCT03529045 record still lists
NCT03529045 is an observational study that tracks outcomes without assigning an intervention. The registered 827 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Vagus Nerve Stimulation (VNS) Therapy is the first listed.
NCT03529045 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03529045 about?
NCT03529045 is a clinical study titled "Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.". Multicenter global post-market registry of subjects diagnosed with drug resistant epilepsy and treated with the VNS Therapy System.
What is the current status of trial NCT03529045?
This trial is currently completed. The enrollment target is 827 participants. The study started on 2018-02-05. Estimated completion is 2024-09-11.
What interventions are being tested in trial NCT03529045?
The interventions under investigation include: Vagus Nerve Stimulation (VNS) Therapy (DEVICE).
Who is sponsoring clinical trial NCT03529045?
This trial is sponsored by LivaNova, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03547973 · 827 participants · Phase 2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
- NCT05124808 · 828 participants · NA
Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- NCT05630482 · 825 participants · NA
Randomized Trial of Healthy Family Foundations
- NCT06097728 · 825 participants · Phase 3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI